Loading…

Population pharmacokinetics and biodistribution of benznidazole in mice

To evaluate the population pharmacokinetics of different benznidazole treatment regimens and the drug's biodistribution in mice. Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2020-08, Vol.75 (8), p.2213
Main Authors: Perin, Luísa, Pinto, Leonardo, Balthazar Nardotto, Glauco Henrique, da Silva Fonseca, Kátia, Oliveira Paiva, Beatriz, Fernanda Rodrigues Bastos Mendes, Thaís, Molina, Israel, Correa-Oliveira, Rodrigo, Melo de Abreu Vieira, Paula, Martins Carneiro, Cláudia
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963
cites cdi_FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963
container_end_page
container_issue 8
container_start_page 2213
container_title Journal of antimicrobial chemotherapy
container_volume 75
creator Perin, Luísa
Pinto, Leonardo
Balthazar Nardotto, Glauco Henrique
da Silva Fonseca, Kátia
Oliveira Paiva, Beatriz
Fernanda Rodrigues Bastos Mendes, Thaís
Molina, Israel
Correa-Oliveira, Rodrigo
Melo de Abreu Vieira, Paula
Martins Carneiro, Cláudia
description To evaluate the population pharmacokinetics of different benznidazole treatment regimens and the drug's biodistribution in mice. Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/day for 20 days; (4) 40 mg/kg/day for 20 days; or (5) 40 mg/kg/day for 40 days. The mice were euthanized and blood, heart, liver, colon and brain were collected. Samples were prepared by liquid-liquid extraction and analysed by HPLC-diode-array detection. The pharmacokinetic analysis of benznidazole was evaluated via non-linear mixed-effects modelling using the NONMEN program. Our results demonstrate that mouse weight allometrically influences benznidazole clearance; the AUC curve and the highest plasma concentration are dose proportional; benznidazole does not influence its own metabolism; its tissue distribution is limited; and the standard treatment regimen for Chagas' disease in mice (100 mg/kg/day for 20 days) is inadequate from a pharmacokinetic standpoint, as are the other regimens tested in this study (100 mg/kg/day for 40 days, 200 mg/kg/day for 20 days and 40 mg/kg/day for 20 or 40 days). Benznidazole reformulations that allow better tissue penetration and plasma and tissue exposure should be evaluated to enable higher cure rates in both animals and patients. The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease. Determining appropriate treatment regimens in animals allows translation of these to clinical studies.
doi_str_mv 10.1093/jac/dkaa130
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_jac_dkaa130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32356873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963</originalsourceid><addsrcrecordid>eNo9kDtPwzAURi0EoqUwsSPvKNTOje1kRBUUpEowdI9u_BBukziKk4H-ekJbmO5DR5_0HULuOXvirIDlDvXS7BE5sAsy55lkScoKfknmDJhIVCZgRm5i3DHGpJD5NZlBCtOiYE7Wn6Ebaxx8aGn3hX2DOux9awevI8XW0MoH4-PQ-2o8QsHRyraH1hs8hNpS39LGa3tLrhzW0d6d54JsX1-2q7dk87F-Xz1vEg2pHBIuVAbghCwwz8x0pICaV-CszPJ8-ktMnVZccOmUBZcrZVIuJkQaXkhYkMdTrO5DjL11Zdf7BvvvkrPy10Y52SjPNib64UR3Y9VY88_-1YcfZ2tcYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Population pharmacokinetics and biodistribution of benznidazole in mice</title><source>Oxford Journals Online</source><creator>Perin, Luísa ; Pinto, Leonardo ; Balthazar Nardotto, Glauco Henrique ; da Silva Fonseca, Kátia ; Oliveira Paiva, Beatriz ; Fernanda Rodrigues Bastos Mendes, Thaís ; Molina, Israel ; Correa-Oliveira, Rodrigo ; Melo de Abreu Vieira, Paula ; Martins Carneiro, Cláudia</creator><creatorcontrib>Perin, Luísa ; Pinto, Leonardo ; Balthazar Nardotto, Glauco Henrique ; da Silva Fonseca, Kátia ; Oliveira Paiva, Beatriz ; Fernanda Rodrigues Bastos Mendes, Thaís ; Molina, Israel ; Correa-Oliveira, Rodrigo ; Melo de Abreu Vieira, Paula ; Martins Carneiro, Cláudia</creatorcontrib><description>To evaluate the population pharmacokinetics of different benznidazole treatment regimens and the drug's biodistribution in mice. Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/day for 20 days; (4) 40 mg/kg/day for 20 days; or (5) 40 mg/kg/day for 40 days. The mice were euthanized and blood, heart, liver, colon and brain were collected. Samples were prepared by liquid-liquid extraction and analysed by HPLC-diode-array detection. The pharmacokinetic analysis of benznidazole was evaluated via non-linear mixed-effects modelling using the NONMEN program. Our results demonstrate that mouse weight allometrically influences benznidazole clearance; the AUC curve and the highest plasma concentration are dose proportional; benznidazole does not influence its own metabolism; its tissue distribution is limited; and the standard treatment regimen for Chagas' disease in mice (100 mg/kg/day for 20 days) is inadequate from a pharmacokinetic standpoint, as are the other regimens tested in this study (100 mg/kg/day for 40 days, 200 mg/kg/day for 20 days and 40 mg/kg/day for 20 or 40 days). Benznidazole reformulations that allow better tissue penetration and plasma and tissue exposure should be evaluated to enable higher cure rates in both animals and patients. The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease. Determining appropriate treatment regimens in animals allows translation of these to clinical studies.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkaa130</identifier><identifier>PMID: 32356873</identifier><language>eng</language><publisher>England</publisher><ispartof>Journal of antimicrobial chemotherapy, 2020-08, Vol.75 (8), p.2213</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963</citedby><cites>FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963</cites><orcidid>0000-0002-8181-4764 ; 0000-0001-7024-4252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32356873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perin, Luísa</creatorcontrib><creatorcontrib>Pinto, Leonardo</creatorcontrib><creatorcontrib>Balthazar Nardotto, Glauco Henrique</creatorcontrib><creatorcontrib>da Silva Fonseca, Kátia</creatorcontrib><creatorcontrib>Oliveira Paiva, Beatriz</creatorcontrib><creatorcontrib>Fernanda Rodrigues Bastos Mendes, Thaís</creatorcontrib><creatorcontrib>Molina, Israel</creatorcontrib><creatorcontrib>Correa-Oliveira, Rodrigo</creatorcontrib><creatorcontrib>Melo de Abreu Vieira, Paula</creatorcontrib><creatorcontrib>Martins Carneiro, Cláudia</creatorcontrib><title>Population pharmacokinetics and biodistribution of benznidazole in mice</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>To evaluate the population pharmacokinetics of different benznidazole treatment regimens and the drug's biodistribution in mice. Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/day for 20 days; (4) 40 mg/kg/day for 20 days; or (5) 40 mg/kg/day for 40 days. The mice were euthanized and blood, heart, liver, colon and brain were collected. Samples were prepared by liquid-liquid extraction and analysed by HPLC-diode-array detection. The pharmacokinetic analysis of benznidazole was evaluated via non-linear mixed-effects modelling using the NONMEN program. Our results demonstrate that mouse weight allometrically influences benznidazole clearance; the AUC curve and the highest plasma concentration are dose proportional; benznidazole does not influence its own metabolism; its tissue distribution is limited; and the standard treatment regimen for Chagas' disease in mice (100 mg/kg/day for 20 days) is inadequate from a pharmacokinetic standpoint, as are the other regimens tested in this study (100 mg/kg/day for 40 days, 200 mg/kg/day for 20 days and 40 mg/kg/day for 20 or 40 days). Benznidazole reformulations that allow better tissue penetration and plasma and tissue exposure should be evaluated to enable higher cure rates in both animals and patients. The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease. Determining appropriate treatment regimens in animals allows translation of these to clinical studies.</description><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kDtPwzAURi0EoqUwsSPvKNTOje1kRBUUpEowdI9u_BBukziKk4H-ekJbmO5DR5_0HULuOXvirIDlDvXS7BE5sAsy55lkScoKfknmDJhIVCZgRm5i3DHGpJD5NZlBCtOiYE7Wn6Ebaxx8aGn3hX2DOux9awevI8XW0MoH4-PQ-2o8QsHRyraH1hs8hNpS39LGa3tLrhzW0d6d54JsX1-2q7dk87F-Xz1vEg2pHBIuVAbghCwwz8x0pICaV-CszPJ8-ktMnVZccOmUBZcrZVIuJkQaXkhYkMdTrO5DjL11Zdf7BvvvkrPy10Y52SjPNib64UR3Y9VY88_-1YcfZ2tcYQ</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Perin, Luísa</creator><creator>Pinto, Leonardo</creator><creator>Balthazar Nardotto, Glauco Henrique</creator><creator>da Silva Fonseca, Kátia</creator><creator>Oliveira Paiva, Beatriz</creator><creator>Fernanda Rodrigues Bastos Mendes, Thaís</creator><creator>Molina, Israel</creator><creator>Correa-Oliveira, Rodrigo</creator><creator>Melo de Abreu Vieira, Paula</creator><creator>Martins Carneiro, Cláudia</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-8181-4764</orcidid><orcidid>https://orcid.org/0000-0001-7024-4252</orcidid></search><sort><creationdate>20200801</creationdate><title>Population pharmacokinetics and biodistribution of benznidazole in mice</title><author>Perin, Luísa ; Pinto, Leonardo ; Balthazar Nardotto, Glauco Henrique ; da Silva Fonseca, Kátia ; Oliveira Paiva, Beatriz ; Fernanda Rodrigues Bastos Mendes, Thaís ; Molina, Israel ; Correa-Oliveira, Rodrigo ; Melo de Abreu Vieira, Paula ; Martins Carneiro, Cláudia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perin, Luísa</creatorcontrib><creatorcontrib>Pinto, Leonardo</creatorcontrib><creatorcontrib>Balthazar Nardotto, Glauco Henrique</creatorcontrib><creatorcontrib>da Silva Fonseca, Kátia</creatorcontrib><creatorcontrib>Oliveira Paiva, Beatriz</creatorcontrib><creatorcontrib>Fernanda Rodrigues Bastos Mendes, Thaís</creatorcontrib><creatorcontrib>Molina, Israel</creatorcontrib><creatorcontrib>Correa-Oliveira, Rodrigo</creatorcontrib><creatorcontrib>Melo de Abreu Vieira, Paula</creatorcontrib><creatorcontrib>Martins Carneiro, Cláudia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perin, Luísa</au><au>Pinto, Leonardo</au><au>Balthazar Nardotto, Glauco Henrique</au><au>da Silva Fonseca, Kátia</au><au>Oliveira Paiva, Beatriz</au><au>Fernanda Rodrigues Bastos Mendes, Thaís</au><au>Molina, Israel</au><au>Correa-Oliveira, Rodrigo</au><au>Melo de Abreu Vieira, Paula</au><au>Martins Carneiro, Cláudia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Population pharmacokinetics and biodistribution of benznidazole in mice</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>75</volume><issue>8</issue><spage>2213</spage><pages>2213-</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>To evaluate the population pharmacokinetics of different benznidazole treatment regimens and the drug's biodistribution in mice. Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/day for 20 days; (4) 40 mg/kg/day for 20 days; or (5) 40 mg/kg/day for 40 days. The mice were euthanized and blood, heart, liver, colon and brain were collected. Samples were prepared by liquid-liquid extraction and analysed by HPLC-diode-array detection. The pharmacokinetic analysis of benznidazole was evaluated via non-linear mixed-effects modelling using the NONMEN program. Our results demonstrate that mouse weight allometrically influences benznidazole clearance; the AUC curve and the highest plasma concentration are dose proportional; benznidazole does not influence its own metabolism; its tissue distribution is limited; and the standard treatment regimen for Chagas' disease in mice (100 mg/kg/day for 20 days) is inadequate from a pharmacokinetic standpoint, as are the other regimens tested in this study (100 mg/kg/day for 40 days, 200 mg/kg/day for 20 days and 40 mg/kg/day for 20 or 40 days). Benznidazole reformulations that allow better tissue penetration and plasma and tissue exposure should be evaluated to enable higher cure rates in both animals and patients. The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease. Determining appropriate treatment regimens in animals allows translation of these to clinical studies.</abstract><cop>England</cop><pmid>32356873</pmid><doi>10.1093/jac/dkaa130</doi><orcidid>https://orcid.org/0000-0002-8181-4764</orcidid><orcidid>https://orcid.org/0000-0001-7024-4252</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2020-08, Vol.75 (8), p.2213
issn 0305-7453
1460-2091
language eng
recordid cdi_crossref_primary_10_1093_jac_dkaa130
source Oxford Journals Online
title Population pharmacokinetics and biodistribution of benznidazole in mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Population%20pharmacokinetics%20and%20biodistribution%20of%20benznidazole%20in%20mice&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Perin,%20Lu%C3%ADsa&rft.date=2020-08-01&rft.volume=75&rft.issue=8&rft.spage=2213&rft.pages=2213-&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkaa130&rft_dat=%3Cpubmed_cross%3E32356873%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-157433f569a84d57423ac1b3fe6488f566a2fc71516f7e3f877d215c1b6d1963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32356873&rfr_iscdi=true